JP2021503490A5 - - Google Patents

Download PDF

Info

Publication number
JP2021503490A5
JP2021503490A5 JP2020543658A JP2020543658A JP2021503490A5 JP 2021503490 A5 JP2021503490 A5 JP 2021503490A5 JP 2020543658 A JP2020543658 A JP 2020543658A JP 2020543658 A JP2020543658 A JP 2020543658A JP 2021503490 A5 JP2021503490 A5 JP 2021503490A5
Authority
JP
Japan
Prior art keywords
compound according
compound
formula
derivative
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020543658A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021503490A (ja
JP7282792B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2018/051336 external-priority patent/WO2019075583A1/en
Publication of JP2021503490A publication Critical patent/JP2021503490A/ja
Publication of JP2021503490A5 publication Critical patent/JP2021503490A5/ja
Priority to JP2023081323A priority Critical patent/JP7592120B2/ja
Application granted granted Critical
Publication of JP7282792B2 publication Critical patent/JP7282792B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020543658A 2017-10-22 2018-10-22 前立腺特異的膜抗原発現癌の診断または治療のための新規放射性金属結合化合物 Active JP7282792B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023081323A JP7592120B2 (ja) 2017-10-22 2023-05-17 前立腺特異的膜抗原発現癌の診断または治療のための新規放射性金属結合化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762575460P 2017-10-22 2017-10-22
US62/575,460 2017-10-22
PCT/CA2018/051336 WO2019075583A1 (en) 2017-10-22 2018-10-22 NOVEL RADIOMETAL BINDING COMPOUNDS FOR THE DIAGNOSIS OR TREATMENT OF CANCER EXPRESSING A PROSTATE-SPECIFIC MEMBRANE ANTIGEN

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023081323A Division JP7592120B2 (ja) 2017-10-22 2023-05-17 前立腺特異的膜抗原発現癌の診断または治療のための新規放射性金属結合化合物

Publications (3)

Publication Number Publication Date
JP2021503490A JP2021503490A (ja) 2021-02-12
JP2021503490A5 true JP2021503490A5 (https=) 2021-12-02
JP7282792B2 JP7282792B2 (ja) 2023-05-29

Family

ID=66173073

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020543658A Active JP7282792B2 (ja) 2017-10-22 2018-10-22 前立腺特異的膜抗原発現癌の診断または治療のための新規放射性金属結合化合物
JP2023081323A Active JP7592120B2 (ja) 2017-10-22 2023-05-17 前立腺特異的膜抗原発現癌の診断または治療のための新規放射性金属結合化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023081323A Active JP7592120B2 (ja) 2017-10-22 2023-05-17 前立腺特異的膜抗原発現癌の診断または治療のための新規放射性金属結合化合物

Country Status (8)

Country Link
US (2) US20200339625A1 (https=)
EP (1) EP3700917A4 (https=)
JP (2) JP7282792B2 (https=)
KR (1) KR102884167B1 (https=)
CN (1) CN111630059B (https=)
AU (1) AU2018352731B2 (https=)
CA (1) CA3079906A1 (https=)
WO (1) WO2019075583A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018204477A1 (en) 2017-05-02 2018-11-08 Cornell University Methods and reagents for tumor targeting with greater efficacy and less toxicity
US20200297877A1 (en) 2017-12-13 2020-09-24 Sciencons AS Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide
AU2020257786B2 (en) * 2019-04-17 2025-10-23 Provincial Health Services Authority Novel radiolabelled compounds for diagnosis or treatment of prostate-specific membrane antigen-expressing cancer
CN110317151B (zh) * 2019-06-06 2022-06-24 原子高科股份有限公司 前列腺癌PET诊断试剂68Ga-HBBED-ANCP-PSMA及其制备方法和应用
BR112021025810A2 (pt) * 2019-06-21 2022-05-10 Provincial Health Services Authority Compostos radiomarcados direcionando o antígeno de membrana específico da próstata
AU2021230210A1 (en) * 2020-03-04 2022-09-22 Kyoto University Compound and radioactive labeling compound
EP4263509A4 (en) * 2020-12-16 2024-12-04 The University of British Columbia RADIOACTIVELY LABELLED COMPOUNDS FOR TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN
WO2022167681A1 (en) * 2021-02-08 2022-08-11 Stichting Radboud Universitair Medisch Centrum Psma-targeting ligands for multimodal applications
AU2022228911A1 (en) 2021-03-04 2023-09-21 Kyoto University Compound and radioactive labeling compound
CN116940557A (zh) * 2021-03-04 2023-10-24 日本医事物理股份有限公司 化合物及放射性标记化合物
CN113372285B (zh) * 2021-05-28 2024-06-18 西南医科大学附属医院 前列腺特异性膜抗原抑制剂、其放射性核素标记物及制法和应用
CN118852043A (zh) * 2021-09-03 2024-10-29 晶核生物医药科技(南京)有限公司 一种肽脲素衍生物、含其的药物组合物及其应用
CN115806529A (zh) * 2021-09-15 2023-03-17 威智医药有限公司 Psma结合剂及其用途
WO2023083209A1 (zh) * 2021-11-10 2023-05-19 苏州瑞核医药科技有限公司 一种靶向psma抗原的配体化合物及其螯合物与用于前列腺癌诊断和治疗的应用
CA3258344A1 (en) 2022-06-07 2023-12-14 Actinium Pharmaceuticals, Inc. CHELETARIANS AND BIFUNCTIONAL CONJUGATES
CN119855612A (zh) * 2022-09-09 2025-04-18 同宜医药(苏州)有限公司 放射性核素偶联药物及其药物组合物和应用
CN116199736B (zh) * 2023-03-01 2025-03-18 西南医科大学附属医院 一种DOTA-Te-PSMA化合物及其应用
CN116217505B (zh) * 2023-03-17 2024-10-01 南京医科大学 用于诊断或治疗表达前列腺特异性膜抗原癌症的新型标记靶向剂
CN116730983B (zh) * 2023-08-10 2023-11-03 山东大学 一种靶向前列腺特异性抗原的化合物及其制备方法与应用
US20250213705A1 (en) 2023-08-23 2025-07-03 Bright Peak Therapeutics Ag Psma targeting ligands and methods of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0621973D0 (en) 2006-11-03 2006-12-13 Philogen Spa Binding molecules and uses thereof
EP3456700A1 (en) 2013-10-18 2019-03-20 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
EP3400229B1 (en) * 2016-01-10 2024-03-06 Provincial Health Services Authority 18/19f-labelled compounds which target the prostate specific membrane antigen
MX2019005742A (es) 2016-11-23 2019-09-13 Cancer Targeted Tech Llc Inhibidores de antigeno de membrana especifico de la prostata (psma) de union a albumina.
CA3060143A1 (en) * 2017-05-24 2018-11-29 Itm Isotopen Technologien Munchen Ag Novel psma-binding agents and uses thereof

Similar Documents

Publication Publication Date Title
JP2021503490A5 (https=)
JP2012511023A5 (https=)
JP2020518674A5 (https=)
JP2023113612A (ja) Psmaを標的としたイメージング及び放射線治療のための金属/放射性金属標識psma阻害剤
RU2019139432A (ru) Фармакокинетическая оптимизация бифункциональных хелатов и их применение
EP4473980A3 (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of psma-expressing cancers
RU2011127468A (ru) Технецкий- и рений-бис(гетероарильные) комплексы и методы их применения для ингибирования psma
JP2010523599A5 (https=)
JP2024514528A5 (https=)
US11530231B2 (en) CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
JP2024536362A5 (https=)
JP2020520902A5 (https=)
JP2016534063A5 (https=)
RU2011127467A (ru) Са-ix специфические радиофармпрепараты для лечения и визуализации злокачественных опухолей
CN109789207B (zh) 用于原位免疫调节的癌症疫苗接种的靶向放射治疗螯合物
JP2010533727A5 (https=)
JP2023179556A5 (https=)
JP2013533228A5 (https=)
JP2012533523A5 (https=)
JP2020507589A5 (https=)
JP2022509220A5 (ja) 腫瘍抗原標的化剤、医薬組成物、癌診断薬又は癌治療薬、in vitro法、及びその化合物
JP2021502368A (ja) 免疫療法に対する抗腫瘍免疫応答を促進するための標的化放射線療法(trt)の使用
JP2016521275A5 (https=)
JP2024544870A5 (https=)
JP2010523477A5 (https=)